
Avenue Therapeutics ATXI
Quarterly report 2025-Q3
added 11-13-2025
Avenue Therapeutics P/CF Ratio 2011-2026 | ATXI
Annual P/CF Ratio Avenue Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.0603 | -0.00239 | -0.302 | -0.103 | -21.2 K | -5.68 | -3.5 | -3.77 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.00239 | -21.2 K | -2.65 K |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
61.2 | $ 20.22 | -2.32 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
-3.44 | $ 0.82 | -3.48 % | $ 4.47 M | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Axsome Therapeutics
AXSM
|
-92.9 | $ 164.71 | -1.01 % | $ 8.19 B | ||
|
AbCellera Biologics
ABCL
|
-7.33 | $ 3.73 | -2.49 % | $ 1.11 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
11.6 | $ 8.5 | -2.63 % | $ 1.39 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
14.6 | $ 23.88 | - | $ 2.92 B | ||
|
Corvus Pharmaceuticals
CRVS
|
-3.93 | $ 18.08 | 1.06 % | $ 868 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Certara
CERT
|
11.2 | $ 7.19 | 1.93 % | $ 1.15 B | ||
|
Eton Pharmaceuticals
ETON
|
16.8 | $ 17.72 | -2.37 % | $ 454 M | ||
|
Exelixis
EXEL
|
13.2 | $ 40.99 | -0.1 % | $ 11.1 B | ||
|
ARCA biopharma
ABIO
|
-8.36 | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-0.401 | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
Galapagos NV
GLPG
|
-8.78 | $ 33.13 | -2.82 % | $ 2.69 B | ||
|
Greenwich LifeSciences
GLSI
|
-15.8 | $ 27.7 | 1.12 % | $ 361 M | ||
|
Genmab A/S
GMAB
|
4.08 | $ 27.67 | -6.69 % | $ 17.7 B | ||
|
Capricor Therapeutics
CAPR
|
-6.07 | $ 26.04 | -3.07 % | $ 697 M | ||
|
Acasti Pharma
ACST
|
-2.73 | - | 4.01 % | $ 150 M | ||
|
Codexis
CDXS
|
-5.9 | $ 0.99 | -2.92 % | $ 72.7 M | ||
|
Halozyme Therapeutics
HALO
|
14.8 | $ 69.39 | -0.67 % | $ 8.32 B | ||
|
Harmony Biosciences Holdings
HRMY
|
4.62 | $ 28.56 | -1.19 % | $ 1.64 B | ||
|
ImmuCell Corporation
ICCC
|
114 | $ 6.3 | -3.67 % | $ 51.5 M | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
Immuron Limited
IMRN
|
-274 | $ 0.75 | -0.69 % | $ 6.43 M | ||
|
Immatics N.V.
IMTX
|
-6.15 | $ 9.86 | -1.3 % | $ 620 M | ||
|
Immunic
IMUX
|
-1.69 | $ 1.1 | 3.3 % | $ 171 M | ||
|
Immunovant
IMVT
|
-6 | $ 26.99 | -2.74 % | $ 4.09 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
Inhibrx
INBX
|
-9.03 | $ 75.96 | -1.97 % | $ 3.58 B | ||
|
InMed Pharmaceuticals
INM
|
-0.235 | $ 0.75 | -8.49 % | $ 1.84 M | ||
|
INmune Bio
INMB
|
-17.6 | $ 1.41 | 6.07 % | $ 25.4 M | ||
|
Insmed Incorporated
INSM
|
-33.8 | $ 146.89 | 0.39 % | $ 29.2 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-1.3 | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-0.000958 | $ 3.19 | -4.49 % | $ 1.14 M | ||
|
Innate Pharma S.A.
IPHA
|
-6.2 | $ 1.63 | -1.21 % | $ 235 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.224 | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
-4.37 | $ 29.11 | -0.31 % | $ 1.69 B |